Citigroup
PTGX icon

Citigroup’s Protagonist Therapeutics PTGX Stock Holding History

Citigroup’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,400
Closed -$584K – 5691
2023
Q1 		$584K Buy
+25,400
New +$427K ﹤0.01% 3008

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Citigroup's PTGX Position: Q1 2026 in Review

Citigroup increased its Protagonist Therapeutics (PTGX) stake by 67% in Q1 2026, buying an estimated $5.65M and bringing the position to 158,711 shares worth $16.7M. The position accounts for 0.01% of the portfolio, ranked #1174.

Citigroup first reported a position in PTGX in Q3 2016 and has held it in 36 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Citigroup held 158,711 shares of Protagonist Therapeutics worth $16.7M as of Q1 2026.
  • Citigroup bought 63,802 Protagonist Therapeutics shares in Q1 2026, an estimated $5.65M.
  • Protagonist Therapeutics made up 0.01% of Citigroup's portfolio in Q1 2026, its #1174 holding.
  • Citigroup first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 36 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.